Fostemsavir plus optimized background therapy was associated with improvements in immune biomarkers among HTE patients with MDR HIV infection.

Several urged for increased education and awareness among healthcare providers to reduce stigma when treating HIV ...

In this randomized controlled trial, among adolescent girls and young women, it was found that twice-yearly lenacapavir ...

Alchemy, which sets up pharmacies in community clinics, said that it had raised $31 million from Andreessen Horowitz and ...

In June, we heard what could be this year’s biggest HIV breakthrough: a twice-yearly injection can prevent HIV infection. A ...

As one of the largest pharmaceutical and vaccine companies, GSK has used its vast resources to create the next generation of healthcare treatments. The company's innovative new product lineup and ...

New data from the PURPOSE 2 trial continue to show the efficacy of lenacapavir in HIV prevention in individuals who have sex ...

in combination with an optimized background regimen in people with multi-drug resistant HIV. HIV prevention data will include an analysis of newly initiated pre-exposure prophylaxis (PrEP ...

Spotted in a various beta update, the Meta-owned platform was quite interested in adding filters and backgrounds to the video calls. After being under testing for a long time, WhatsApp has announced ...

Per the data readout, it was observed that the candidate, administered twice a year, demonstrated superior efficacy over the once-daily oral dose of Truvada and background HIV incidence.

Prof Salim is a public health physician, epidemiologist, and virologist whose research interests span HIV treatment and prevention. Prof Quarraisha is an infectious diseases epidemiologist and the ...

Professor of medicine and deputy director of the Desmond Tutu HIV Centre at the Institute of Infectious Disease and Molecular Medicine, University of Cape Town A new drug to prevent HIV infection ...